The Online International  Journal of Onco Scientific Networks & Oncology is a peer-reviewed open acess journal that publishes original research articles as well as review articles in all areas of Oncology. this practical journal also includes information on new products, new therapies and patient management, as well as reviews of the latest research. Cancer is a complex problem. The international effort to understand and control it involves clinicians trained in many branches of medicine and scientists from most biological disciplines, chemistry, pharmaceutical and physical sciences The International Online Journal of Cancer & Therapeutics exists to serve the needs of this diverse community, providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

The journal publishes important original studies, reviews, and perspectives within the major topic areas of biology of premalignancy, risk factors and risk assessment, early detection research, immunoprevention, and chemopreventive and other interventions, including the basic science behind them. This journal comprises preclinical, clinical and translational research, with special attention given to molecular discoveries and an emphasis on building a translational bridge between the basic and clinical sciences. Main focuses of interest include: systemic anticancer therapy (with specific interest on molecular targeted agents and new immune therapies), randomized trials (including negatives ones), top-level guidelines, and new fields currently emerging as key components of personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Radiotherapy, surgery and pediatrics manuscripts can be considered if they display a clear interaction with one of the fields above or are paradigm-shifting.

Oncology is the diagnosis and treatment of cancers,including breast,prostate,colon,lung and ovarian cancers as well as brain tumors,leukemia,lymphoma and many other types of cancer.. A doctor who works in the field of oncology is called an oncologist. The primary regions of oncology are radiation, which is worried with radiation treatment, or radiotherapy; surgical, which is contained specialists who spend significant time in tumor evacuation; therapeutic, which manages disease drugs, including chemotherapy; and interventional, which includes interventional radiologists who have some expertise in insignificantly obtrusive picture guided tumor treatment.


committee

Members

ThumbnailImage

Aliaksandr V Prokharau

Professor

  • Minsk State Medical Institute, Minsk, Belorussia , USSR, 1975 -1981
  • Internship (Surgery), Minsk State Medical University, Minsk, Belorussia, USSR, 1981 -1982 Surgeon, City Clinical Hospital #2, Minsk, Belorussia, USSR, 1982-1986
  • Research Fellowship (Surgery), City Clinical Hospital #2 affiliated with Surgery Diseases Department #3, , Belorussia, USSR, 1986 -1989
  • Research of Medical Science, Minsk State Medical University, Minsk, Belarus 2005
  • Course in GCP, Center for Expertizes and Researches in Healthcare, Minsk, Belarus, 2009
  • Advanced Course in Oncology, Republican Scientific Practical Center of Oncology and Medical Radiology, Minsk, Belarus, 2010
  • Investigator Site GCP Training Certificate, Celltrion, 2010
  • Certificate of Oncologist 2010
  • Certificate of Oncologist 2012
  • Investigator Site Personnel ICH GCP Training Certificate, Pfizer, 2014
  • Investigator Site Personnel ICH GCP Training Certificate, Roche, 2014
  • Certificate of Oncologist 2015
  • NIDA Clinical Trials Network Certificate of Completion GCP 2017
  • Certificate of Oncologist 2017
  • State Prize of the Republic of Belarus 2005
  • Honorary Diploma of the National Academy of Sciences of the Republic of Belarus
  • Honorary Diploma of the Ministry of Health of the Republic of Belarus
  • Member of Editorial Board “Cancer and Clinical Oncology”
  • Member of Editorial Board “JSM Surgical Oncology and Research”
  • Member of Editorial Board “Austin Pain & Relief”
  • Member of Editorial Board “Medical Journal” (Belarus)
  • Member of Editorial Board “Military medicine” (Belarus)
  • Member of Editorial Board International scientific journal “SURGERY Eastern Europe” (Belarus, Ukraine, Azerbaijan)

 

 

  1. Prochorov AV., Tretjak SI., Roudenok VV., Goranov VA. Long-term normalization of diabetes mellitus after xenotransplantation of fetal pancreatic islet cells into the blood stream without immunosuppressive. Transpl.Proc.2004, vol.36 (issue9):2855-2856
  2. Prochorov AV, Roudenok VV, Goranov VA. Histological study of macroencapsulation of pancreatic islet cells after transplantation into the blood stream. Transpl.Proc.2005, vol.37, (issue 10):.4446-4448.
  3. Tretyak S, Prochorov A, Khryshchanovich V, Nedzvedz M, Romanovich A. Long-term preservation of vitality of xenogenicthyrocytes in the recipient after their transplantation into the blood stream. Advances in Medical Sciences. 2008, vol.53:1-4.
  4. Prochorov AV, Tretjak SI, Goranov VA, Glinnik AA, Goltsev MV. Treatment of insulin dependent diabetes mellitus with intravascular transplantation of pancreatic islet cells without immunosuppressive therapy. Advances in Medical Sciences.2008, vol.53 (2): 240-244
  5. Prochorov AV, Oldhafer KJ, Tretyak SI, Rashchynski SM, Donati M, Rashchynskaya NT, Audzevich DA. Surgical treatment of pain in patients with chronic pancreatitis//Hepato-Gastroenterology. 2012; 59(116):1265-9
  6. Prochorov A, Labunec I, Kazakevich V, Shepetjko M and Papok V. Gastric Cancer in Young Patients Under The Age of 30 Years // J Cancer SciClinOncol 2015, 1(2): 202-205.
  7. Krupnova E.V., Shapetska M.N., Mikhalenko E.P., Chebotaryova N.V., Shchyuk A.N., Pissarchik S.N., Prokhorov A.V. Role of vascular endothelial growth factor in non-small cell lung cancer pathogenesis// Exp.Oncol., 2015, 37 (3): 213-217.
  8. Prochorov AV, Labunec IN, Shepetjko MN, Mavrichev YV and Gedrevich ZE Gastroesophageal Cancer: Prognostic Factors and Treatment Results // Cancer SciClinOncol. 2016 3(1): 104-10
  9. Won Seog Kim, MD, Christian Buske, MD, Michinori Ogura, MD, WojciechJurczak, MD, Juan-Manuel Sancho, MD, EdvardZhavrid, MD, Jin Seok Kim, MD, José-Ángel Hernández-Rivas, MD, AliaksandrProkharau, MD, et.al.. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.The Lancet Haematology, 2017, vol. 4, (8):362–373.
  10. Talayeva S., Kaidarova D., Zhavrid E., Prokharau A., Antonenkova N., Shatkovskaya O., Manasheva A., Rutzhanova Z. Assessment of safety and tolerability of Herceptin subcutaneous administration in patients with HER2-positive early breast cancer: results of an open-label, randomized, multicenter, phase IIIB study. 15th St.Gallen International Breast Cancer Conference 2017, Vienna, Austria 15-18 March 2017, P015, S27
  11. Won Seog Kim, WojciechJurczak, Juan-Manuel Sancho, EdvardJavrid, Jin Seok Kim, Jose Angel Hernandez Rivas, AliaksandrProkharau, et al. Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma. J.Clinical Oncology. May 2017, #7532
  12. Labunec I., ProchorovА.,Shepetjko M., Bozhok P. Treatment results and prognostic factors by gastroesophageal cancer. SEEMF. First international medical conference. Thessaloniki, Greece 16-18 June 2016. P.17-18
  13. Labunec I., ProchorovА.,Shepetjko M., Bozhok P. Treatment results gastric cancer in patients under the age of 30 years. SEEMF. First international medical conference. Thessaloniki, Greece 16-18 June 2016. P.18-19